Login
Toggle sidebar

Lint: acral-fibromyxoma

Strong List Colon Position
error

"T1: isointense to muscle"

Line 57:8 · When enboldening an intro, the colon should not be bold. '<strong>T1:</strong> isointense'

"T2: hyperintense"

Line 58:8 · When enboldening an intro, the colon should not be bold. '<strong>T2: </strong>hyperintense'

"STIR: hyperintense"

Line 59:8 · When enboldening an intro, the colon should not be bold. '<strong>STIR: </strong> hyperintense'

"T1 C+ (Gd): heterogeneous enhancement"

Line 60:8 · When enboldening an intro, the colon should not be bold. '<strong>T1 C+ (Gd):</strong> heterogeneous'
Strong
warning

"Acral fibromyxomas are rare. Most tumours are seen in middle-aged adults, however, they can occur in a wide age range. There is a male predilection 1,3,4."

Line 5:4 · Generally, don't use bold in text: 'Acral fibromyxomas<strong> </strong>are rare. Most tumours are seen in middle-aged adults, however, they can occur in a wide age range. There is a male predilection'
Emphasis
warning

"On immunohistochemistry stains, tumour cells usually express CD34, CD99 and vimentin. Occasional positivity of epithelial membrane antigen and smooth muscle actin is seen. A loss of RB1 expression can be observed 1, 3-6."

Line 45:221 · Italics should be used only in exceptional circumstances: '<em>RB1</em>'
Headings Valid
warning

Expected headings

  • H1 Terminology
  • H1 Usage
  • H1 Epidemiology
  • H2 Risk factors
  • H2 Associations
  • H1 Clinical presentation
  • H2 Complications
  • H1 Diagnosis
  • H2 Diagnostic criteria
  • H2 Diagnostic clues
  • H1 Pathology
  • H2 Aetiology
  • H2 Location
  • H2 Classification
  • H2 Macroscopic appearance
  • H2 Microscopic appearance
  • H2 Immunophenotype
  • H2 Markers
  • H2 Genetics
  • H1 Radiographic features
  • H2 Plain radiograph
  • H2 Mammography
  • H2 Antenatal ultrasound
  • H2 Transoesophageal echocardiography
  • H2 Ultrasound
  • H2 CT
  • H3 Dual-energy CT
  • H2 Angiography (DSA)
  • H2 MRI
  • H2 CT/MRI
  • H2 Nuclear medicine
  • H3 PET-CT
  • H3 PET-MRI
  • H1 Radiology report
  • H1 Treatment and prognosis
  • H2 Complications
  • H1 History and etymology
  • H1 Differential diagnosis
  • H2 Clinical differential diagnosis
  • H1 Practical points
  • H1 See also

"Associations"

Line 23:1 · "Associations" is under the wrong parent heading (found under "Clinical presentation").

"Signal characteristics"

Line 55:1 · "Signal characteristics" is not a recognised heading for this article type.
There Is
suggestion

"Acral fibromyxomas are rare. Most tumours are seen in middle-aged adults, however, they can occur in a wide age range. There is a male predilection 1,3,4."

Line 5:140 · Don't start a sentence with 'There is'.

"The treatment of choice is surgical excision. Local recurrence can happen in up to one-fourth of the cases, but are non-destructive and can be cured by re-excision. There are no reported metastases 1,3,4,6."

Line 69:169 · Don't start a sentence with 'There are'.
Oxford Comma
suggestion

"lobulated structure with fascicular, whorled or storiform growth pattern"

Line 13:33 · Use the Oxford comma in 'fascicular, whorled or storiform'.

"Acral fibromyxoma is a skin-based nonencapsulated fibroblastic proliferation leading to an infiltration of the subcutaneous tissue. They are characterised by lobular architecture with fascicular, palisading or storiform growth patterns 1,3."

Line 26:188 · Use the Oxford comma in 'fascicular, palisading or storiform'.

"Acral fibromyxomas are usually found in an acral periungual and subungual location of the fingers and toes. On rare occasions, they might be seen in other areas of the extremities such as hands and feet ankles, wrists or lower legs and thighs 1,3-5."

Line 30:207 · Use the Oxford comma in 'ankles, wrists or lower'.

"On immunohistochemistry stains, tumour cells usually express CD34, CD99 and vimentin. Occasional positivity of epithelial membrane antigen and smooth muscle actin is seen. A loss of RB1 expression can be observed 1, 3-6."

Line 45:75 · Use the Oxford comma in 'CD34, CD99 and vimentin'.